A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Study Identifier:
382-201-00001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
N/A
Active, Not Recruiting
Subscribe to Updates

Study Details

Medical Condition
  • Depression
Study Drug
  • Drug: SEP-363856
Date
Nov 2022 - Nov 2025
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years
Requirements Information

Protocol Summary

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate respons

Study Locations

Location
Status
Location
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Status
N/A
Location
Scottsdale Clinical Research
Scottsdale, Arizona, United States, 85260
Status
N/A
Location
ProScience Research Group
Culver City, California, United States, 90230
Status
N/A
Location
Wr-Pri, Llc
Encino, California, United States, 91316
Status
N/A
Location
Collaborative NeuroScience Research , LLC
Garden Grove, California, United States, 92845
Status
N/A
Location
Alliance Research
Long Beach, California, United States, 90807
Status
N/A
Go to page
© 2025 Otsuka America Pharmaceutical, Inc.
All rights reserved.

July 2025 01US25EUC0279